The trial design change improves the near-term regulatory pathway for PDS0101, potentially accelerating value inflection, but the shrinking cash balance (~$26.7M) relative to operating costs (~$31.5M in 2025) suggests a capital raise is likely within the next 9–12 months, which would be dilutive. Monitor upcoming clinical updates on PDS01ADC and enrollment progress in the amended VERSATILE-003 trial.
Price Chart
Executive Summary
PDS Biotechnology reported financial results for 2025 and provided a clinical update, including a Phase 3 trial amendment for its lead candidate PDS0101 to incorporate progression-free survival as an interim primary endpoint, which could enable accelerated approval in HPV16-positive head and neck cancer. The company reduced operating expenses and improved net loss compared to 2024, but ended the year with $26.7 million in cash, down from $41.7 million, raising concerns about runway. Early data from a PDS01ADC trial showed promising median PFS of 9.6 months in prostate cancer.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $34.5 million ($0.74/share), improved from $37.6 million ($1.03/share) in 2024.
- R&D expenses decreased to $19.0 million from $22.6 million in 2024, driven by lower manufacturing and personnel costs.
- Cash balance declined to $26.7 million as of December 31, 2025, from $41.7 million in 2024, a 36% reduction.
- Amended VERSATILE-003 Phase 3 trial to include PFS as an interim primary endpoint to potentially accelerate approval for PDS0101.
- Early PDS01ADC + docetaxel data in mCRPC showed 9.6 months median PFS and 40% median PSA decline.
- New U.S. and Japanese patents extend PDS0101 IP protection into the 2040s.
Financial Impact
Reduced annual operating expenses by $4.8 million, but cash burn remains high at ~$15 million net reduction in cash year-over-year.
Risk Factors
- Cash runway may be insufficient to reach key milestones without dilutive financing.
- Accelerated approval pathway depends on PFS data, which may not confirm OS benefit.
- Forward-looking statements dominate messaging; clinical progress remains early-stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264482 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7380 (−146.00%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7380 (+253.28%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7380 (−216.47%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7380 (−187.16%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7380 (−3.14%) |
Jun 26, 2026 13w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7380 (−17.92%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7380 (+23.13%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7380 (−27.65%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7380 (−36.38%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7380 (−44.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access